DEF 14A: Conduit Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Conduit Pharmaceuticals is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Global Market and potentially increase investor interest.

Summary

• Conduit Pharmaceuticals Inc. is holding a virtual annual meeting of stockholders on December 18, 2024, to vote on several proposals.
• The proposals include electing six directors for one-year terms, ratifying the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approving an amendment to the company's certificate of incorporation to effect a reverse stock split.
• The reverse stock split would combine issued shares of common stock by a ratio of not less than 1-for-10 and not more than 1-for-100, with the exact ratio to be determined by the Board of Directors.
• The Board recommends voting FOR all proposals.
• The company received a deficiency letter from Nasdaq on August 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share.
• The company has until February 10, 2025, to regain compliance.
• The Board believes a reverse stock split is the best option to meet the minimum bid price requirement and potentially increase investor interest.
• As of October 25, 2024, there were 100,774,035 shares of Common Stock outstanding.
• The company has until November 12, 2024 to appoint an additional independent director to the audit committee.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to address a negative situation (potential delisting), there is no guarantee of success, and the reverse stock split could have unintended consequences.

Positives

• The Board is taking proactive steps to address the Nasdaq minimum bid price requirement.
• A reverse stock split could potentially increase investor interest and trading volume.
• The company is committed to maintaining its Nasdaq listing.
• The company has until November 12, 2024 to appoint an additional independent director to the audit committee.

Negatives

• The company is currently not in compliance with Nasdaq's minimum bid price requirement.
• There is no guarantee that the reverse stock split will increase the stock price or maintain compliance with Nasdaq listing requirements.
• The liquidity of the Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the Reverse Stock Split.
• The company has until November 12, 2024 to appoint an additional independent director to the audit committee.

Risks

• The reverse stock split may not result in a sustained increase in the stock price.
• The company may still fail to meet Nasdaq's continued listing requirements even after a reverse stock split.
• Reduced liquidity of the Common Stock after the reverse stock split could negatively impact investors.
• The company has until November 12, 2024 to appoint an additional independent director to the audit committee.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements and potentially increase investor interest through a reverse stock split. The Board has discretion to implement the reverse stock split before December 18, 2025.

Management Comments

• The Board believes that seeking stockholder approval and adoption of the Reverse Split Charter Amendment to effect the reverse stock split at the discretion of the Board is advisable and in the best interests of the Company and its stockholders.
• The Board believes that effecting the Reverse Stock Split may be an effective means of avoiding a delisting of the Company's Common Stock from Nasdaq in the future.
• The Board believes that a higher stock price may help generate investor interest in the Company and help the Company attract and retain employees.

Industry Context

Many companies facing similar stock price challenges have considered or implemented reverse stock splits to maintain listing compliance and improve investor perception. The success of such strategies varies depending on company-specific factors and overall market conditions.

Comparison to Industry Standards

• Reverse stock splits are a relatively common strategy for companies facing delisting from major exchanges.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have previously implemented reverse stock splits to maintain Nasdaq compliance.
• The effectiveness of a reverse stock split depends on the underlying fundamentals of the company and its ability to improve its financial performance and market perception.
• The specific ratio chosen for the reverse stock split (between 1-for-10 and 1-for-100) will be crucial in determining its impact on the stock price and investor sentiment.

Management Changes

Corporate Governance

Related Party Transactions

• Corvus Capital Limited (an entity wholly-owned by Dr. Andrew Regan) received 31,148,454 shares of our Common Stock, pursuant to the terms of the Merger Agreement, following the completion of the Business Combination.
• As of October 25, 2024, Corvus Capital owns 30,048,454 shares of our Common Stock directly and 177,627 shares of our Common Stock through its wholly-owned subsidiary, Algo Holdings, Inc., or in the aggregate approximately 30.0% of the outstanding shares of our Common Stock.
• Dr. Regan is also a member of our Board and received director fees of $842,081 during the year ended December 31, 2023.
• Without the Companys knowledge, on or around February and March 2024, Dr. Regan, one of the Companys directors, through Corvus Capital Limited, a wholly owned subsidiary, entered into certain loan and pledge agreements that resulted in the disposition, during the first half of July 2024, of approximately 15 million shares of the Companys Common Stock held by such entity.
• In August 2024, Dr. Regan notified the Company that Corvus Capital, on July 22, 2024, pledged 30,048,454 shares (or 31% of our outstanding Common Stock) in favor of Nirland, a significant stockholder of the Company.
• The shares were pledged pursuant to a participation and inducement agreement that provides, in certain circumstances, Nirland may have a right to cause Corvus Capital to transfer such shares to it.

Stakeholder Impact

• Stockholders face potential dilution and volatility depending on the outcome of the reverse stock split.
• Employees may be affected by changes in the company's stock price and ability to attract and retain talent.
• The company's ability to raise capital and fund operations could be impacted by its Nasdaq listing status.

Next Steps

• Stockholders will vote on the proposals at the annual meeting on December 18, 2024.
• The Board will determine whether to implement the reverse stock split and the specific ratio if approved by stockholders.
• The company must regain compliance with Nasdaq listing requirements by February 10, 2025.
• The company has until November 12, 2024 to appoint an additional independent director to the audit committee.

Key Dates

Keywords

reverse stock split, Nasdaq, proxy statement, annual meeting, directors, Marcum LLP, listing requirements, Conduit Pharmaceuticals, stockholders